Finoriq research workspace
Annexon, Inc. (ANNX) SEC Filings & Filing Highlights
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for. Review ANNX SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
- Company
- Annexon, Inc. (ANNX)
- Ticker
- ANNX
- Market Cap
- $917.5M
- Latest Price
- $5.60
- Industry
- Biotech & Pharma
Annexon, Inc. (ANNX) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Annexon, Inc. (ANNX).
| Event | Form | Date |
|---|---|---|
| Broker Non-VotesAnnexon, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) on June 11, 2026. The following is a brie... | 8-K5.07 | 2026-06-12 |
| Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Mi...Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones | 8-K2.02 | 2026-05-07 |
| Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key...Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones | 8-K2.02 | 2026-03-30 |
| On February 12, 2026, Thomas G. Wiggans, Chairman of the Board of Directors (the “Board”) of An...On February 12, 2026, Thomas G. Wiggans, Chairman of the Board of Directors (the “Board”) of Annexon, Inc. (the “Company”), notified the Co... | 8-K5.02 | 2026-02-17 |
| STOPPING NEUROINFLAMMATION AT ITS SOURCE TH 44 ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE JANUARY...Unlocking a New Era of Care for Neuroinflammatory Diseases Two Blockbuster Registrational Opportunities 1 ~10M Patients and >$10B Global Ma... | 8-K7.01 | 2026-01-14 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.